US03209R1032 - Common Stock
Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84.
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.
BofA initiated coverage of Amphastar Pharmaceuticals (AMPH) with a neutral rating, commenting that it sees its strong business profile already priced into the s
The article discusses the sale of Amphastar Pharmaceuticals shares by director Richard Prins, with transaction value details.